Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species

Describes a panel of novel mAbs that block terminal pathway activation in multiple species by targeting C7 or C7-containing complexes; shows that inhibition downstream of C5 is an attractive target for future therapies.